On May 10, 2026, the highly anticipated "2026 Ningbo Top 100 Brands" list and its series of sub-lists were officially released. Among them, Zhejiang Tianyuan Biotechnology Co., Ltd. was successfully selected for the "2026 Ningbo Top 10 Most Promising New Brands" on the strength of its outstanding technological innovation capabilities and broad market prospects.

      The list was compiled under the authoritative guidance of the Brand Strategy Research Task Force of the Chinese Academy of Social Sciences and the China Marketing Association, and jointly prepared by the China Brand Research Center, the Yongshang Research Institute, and the Ningbo Yongshang Development Research Association. The list focuses on the strength of the new generation of brands, aiming to explore emerging brands across different fields, explore the new connotations of Ningbo brands in the new era, and showcase the innovative vitality and sustainable development momentum of Ningbo's brand ecosystem.

      Zhejiang Tianyuan Biotechnology Co., Ltd.'s success in standing out from numerous participating brands marks the high recognition by academia and industry of its brand strength and development potential in the cell technology field. As an enterprise deeply engaged in the life science and technology sector, Tianyuan Biotechnology takes cell technology as its core and covers a full-life-cycle health management service system. Its business encompasses four major segments: umbilical cord and placenta mesenchymal stem cell storage, immune cell storage, iPS induced pluripotent stem cell storage, and comprehensive immune function assessment. Relying on national-level research platforms such as the National Stem Cell Translational Resource Bank and the Metabolic and Immune Laboratory of the Institute of Science and Technology of the National Health Commission, the company continues to drive technological innovation and industrial translation.

      "We are committed to enabling every family to own its own cell assets," said Jiao Mingming, General Manager of Tianyuan Biotechnology. "This recognition is an acknowledgment of the team's years of dedication, and even more so a new starting point that inspires us to continue honoring life with science and safeguarding promises with professionalism."

      The selection of Zhejiang Tianyuan Biotechnology Co., Ltd. fully demonstrates Ningbo's innovative vitality in precision medicine and hard technology. It is believed that in the future, Tianyuan Biotechnology will continue to uphold its mission of "Gathering the Essence of Science, Safeguarding Human Health," and contribute to the development of the biopharmaceutical industry in Ningbo and across the nation.

      Founded in 2017, Zhejiang Tianyuan Biotechnology Co., Ltd. is a national high-tech enterprise dedicated to the integrated development of cell R&D, production, operations, and services. It holds valuable resource banks including an HLA umbilical cord matching bank, an iPS seed cell bank, and a tumor cell bank, and serves as a formulating unit for the group standard on immune function assessment methods under the National Health Commission. The company has jointly established a Metabolic and Immune Monitoring Joint Laboratory with the Institute of Science and Technology of the National Health Commission, and also serves as the Ningbo Storage Center of the National Stem Cell Translational Resource Bank and the Achievement Translation Center of the Institute of Science and Technology of the National Health Commission, among other important research and service platforms.